| Literature DB >> 25364376 |
Moritz T Giesecke1, Philipp Schwabe1, Florian Wichlas1, Andrej Trampuz1, Christian Kleber1.
Abstract
INTRODUCTION: Emergency treatment of major sub-/total traumatic amputations continue to represent a clinical challenge due to high infection rates and serious handicaps. Effective treatment is based on two columns: surgery and antimicrobial therapy. Detailed identification of pathogen spectrum and epidemiology associated with these injuries is of tremendous importance as it guides the initial empiric antibiotic regimen and prevents adverse septic effents.Entities:
Keywords: Amputation; Antimicrobial therapy; Infection; Open fracture; Pathogen; Pseudomonas; Trauma
Year: 2014 PMID: 25364376 PMCID: PMC4216372 DOI: 10.1186/1749-7922-9-55
Source DB: PubMed Journal: World J Emerg Surg ISSN: 1749-7922 Impact factor: 5.469
Trauma mechanism in sub-/total traumatic amputation
| Trauma mechanism | ||||||||
|---|---|---|---|---|---|---|---|---|
| Injury pattern | Fall | Pedestrian vs. train | Motor-cyclist | Pedestrian vs. auto | Bicyclist | Vehicle occupant | Other | Total |
| n | ||||||||
| Type IIIC open fracture | 11 | 6 | 5 | 6 | 3 | 2 | 2 | 35 |
| Amputation | 1 | 6 | 5 | 2 | 1 | 1 | 0 | 16 |
| Total | 12 | 12 | 10 | 8 | 4 | 3 | 2 | 51 |
Distribution of injury pattern according to underlying trauma mechanism in type IIIC open fractures (subtotal amputations) and total traumatic amputations.
Figure 1Anatomic location of sub-/total traumatic amputations. The lower leg was the predominate injured body region followed by the upper extremity.
Risk factors for infection
| Risk factor | Incidence | |
|---|---|---|
| n | Total % | |
| Diabetes | 1 | 2 |
| Immune deficiency | 0 | 0 |
| Arterial occlusive disease | 1 | 2 |
| Smoker | 3 | 5.9 |
| Alcohol abuse | 1 | 2 |
| Compartment syndrome | 8 | 15.7 |
Risk factors in 51 patients with type IIIC open fractures (subtotal-) and traumatic amputations to acquire infection.
Epidemiology of pathogens in sub-/total traumatic amputation
| 1st wound culture | Acute infection (<14d) | Total | ||
|---|---|---|---|---|
| Pathogen | n | n | n | |
| Bacteria | ||||
| Aerobic | ||||
| Gram-positive | Staphylococcus aureus | 4 | 2 | 7 |
| Bacillus cereus | 6 | 5 | 6 | |
| Enterococcus faecalis | 2 | 2 | 5 | |
| Staphylococcus epidermidis | 2 | 2 | 4 | |
| Enterococcus faecium | 3 | 1 | 3 | |
| Staphylococcus saprophyticus | 1 | 1 | 1 | |
| Staphylococcus capitis | 0 | 1 | 1 | |
| Streptococcus spp. | 1 | 1 | 1 | |
| Rothia mucilaginosa | 1 | 1 | 1 | |
| Lactobacillus spp. | 1 | 1 | 1 | |
| Gram-negative |
|
|
|
|
| E.coli | 3 | 3 | 5 | |
| Enterobacter spp. | 2 | 2 | 5 | |
| Acinetobacter spp. | 3 | 3 | 3 | |
| Pantoea agglomerans | 3 | 3 | 3 | |
| Stenotrophomonas spp. | 0 | 1 | 2 | |
| Acromobacter spp. | 0 | 1 | 2 | |
| Klebsiella spp. | 0 | 1 | 1 | |
| Proteus spp. | 0 | 0 | 1 | |
| Chryseomonas luteola | 1 | 1 | 1 | |
| Acromonas hydrophila | 1 | 1 | 1 | |
| Anaerobic | ||||
| Bacteroides fragiles | 1 | 1 | 1 | |
| Fusobacterium spp. | 1 | 1 | 1 | |
| Anaerococcus prevotei | 1 | 1 | 1 | |
| Clostridium spp. | 0 | 1 | 1 | |
| Fungi | ||||
| Candida spp. | 1 | 0 | 3 | |
| Aspergillus spp. | 1 | 1 | 2 | |
| Paecilomyces ilacinus | 0 | 0 | 1 | |
| Seedosporium spp. | 0 | 0 | 1 | |
| Mucor spp. | 1 | 1 | 1 | |
| Fusarium spp. | 1 | 1 | 1 | |
|
|
|
|
| |
| (>1 species simultaneously) |
Pathogen spectrum of 51 patients with type IIIC open fractures (subtotal-) and traumatic amputations; spp = species. Highest incidence of Pseudomonas spp. and combined pathogens (bolt letters).
Figure 2Temporal incidence of positive polymicrobial and Pseudomonas pathogen proof. Temporal distribution of positive polymicrobial and Pseudomonas pathogen proof in sub-/total traumatic amputations; y-axis: days after trauma; x-axis: admission: Specimen obtain within emergency surgery; early infect: positive pathogen proof within 14 days after trauma; total: incidence of positive pathogen proof within hospitalization period.
Antimicrobial therapy
| Antibiotic agent | n | % |
|---|---|---|
| Ampicillin/Sulbactam | 25 | 49.0 |
| Ampicillin/Sulbactam + Clindamycin | 5 | 9.8 |
| Amoxycillin/Clavulanic acid | 4 | 7.8 |
| Cefuroxime | 3 | 5.9 |
| Cefuroxime + Clindamycin | 2 | 3.9 |
| Ceftriaxone + Clindamycin | 2 | 3.9 |
| Ciprofloxacin + Clindamycin | 2 | 3.9 |
| Clindamycin | 2 | 3.9 |
Empiric antimicrobial therapy and frequency of application.